Table 2.
Laboratory, radiographic and electrocardiographic findings of patients on admission
| Total N = 45 | Survivor N = 34 | Non‐survivor N = 11 | P value | |
|---|---|---|---|---|
| Laboratory findings | ||||
| White blood cell count ×109/L | 5.7 (4.0–7.5) | 5.2 (3.9–7.5) | 5.9 (4.4–8.4) | 0.4840 |
| Neutrophil count ×109/L | 3.8 (2.8–6.8) | 3.7 (2.8–6.0) | 4.4 (2.1–7.4) | 0.4129 |
| Lymphocyte count ×109/L | 0.8 (0.5–1.2) | 0.9 (0.6–1.4) | 0.6 (0.2–0.9) | 0.0223 |
| Monocyte count ×109/L | 0.5 (0.3–0.6) | 0.5 (0.4–0.6) | 0.3 (0.1–0.6) | 0.1424 |
| Red blood cell count ×1012/L | 4.0 (3.4–4.3) | 4.1 (3.7–4.4) | 3.5 (3.1–4.1) | 0.0725 |
| Hemoglobin, g/L | 120.0 (103.0–131.1) | 120.5 (106.0–133.0) | 120.0 (102.0–131.0) | 0.5347 |
| Platelet count ×109/L | 187.0 (133.0–245.0) | 203.0 (160.0–258.0) | 119.0 (66.0–199.0) | 0.0028 |
| <125 | 11 (24.4) | 5 (14.7) | 6 (54.5) | 0.0143 |
| ≥125 | 34 (75.6) | 29 (85.3) | 5 (45.5) | |
| ALT, U/L | 0.7049 | |||
| ≤40 | 34 (75.6) | 25 (73.5) | 9 (81.8) | |
| >40 | 11 (24.4) | 9 (26.5) | 2 (18.2) | |
| AST, U/L | 0.0707 | |||
| ≤40 | 31 (68.9) | 26 (76.5) | 5 (45.5) | |
| >40 | 14 (31.1) | 8 (23.5) | 6 (54.5) | |
| LDH, U/L | ||||
| ≤245 | 21 (53.8) | 18 (58.1) | 3 (37.5) | 0.4324 |
| >245 | 18 (46.2) | 13 (41.9) | 5 (62.5) | |
| Total bilirubin, μmol/L | 0.0125 | |||
| ≤21 | 41 (93.2) | 33 (100) | 8 (72.7) | |
| >21 | 3 (6.8) | 0 (0) | 3 (27.3) | |
| Urea, mmol/L | 5.5 (4.0–8.0) | 4.8 (3.7–6.8) | 8 (7.2–10.9) | 0.0013 |
| Creatinine, μmol/L | 0.1434 | |||
| ≤133 | 42 (93.3) | 33 (97.1) | 9 (81.8) | |
| >133 | 3 (6.7) | 1 (2.9) | 2 (18.2) | |
| PT, s | 11.8 (10.9–12.9) | 11.6 (10.8–12.3) | 13.0 (11.8–13.9) | 0.0168 |
| APTT, s | 29.4 (24.8–32.8) | 29.4 (25.0–32.2) | 30.0 (23.8–38.1) | 0.7311 |
| D‐dimer, mg/L | 2.0 (0.7–10.7) | 1.5 (0.7–3.8) | 19.1 (1.8–37.3) | 0.0096 |
| C‐reactive protein, mg/L | 0.4101 | |||
| <10 | 9 (22) | 8 (25.8) | 1 (10) | |
| ≥10 | 32 (78) | 23 (74.2) | 9 (90) | |
| Procalcitonin, ng/mL | 0.0635 | |||
| <0.5 | 35 (83.3) | 28 (90.3) | 7 (63.6) | |
| ≥0.5 | 7 (16.7) | 3 (9.7) | 4 (36.4) | |
| hs‐TNI | 0.0084 | |||
| Normal | 23 (62.2) | 20 (76.9) | 3 (27.3) | |
| Elevated | 14 (37.8) | 6 (23.1) | 8 (72.7) | |
| CK–MB | 0.6582 | |||
| Normal | 33 (80.5) | 25 (83.3) | 8 (72.7) | |
| Elevated | 8 (19.5) | 5 (16.7) | 3 (27.3) | |
| Myoglobin, ng/mL | 76.9 (35.2–144.6) | 52.8 (30.0–87.7) | 153.2 (100.1–218.3) | 0.0020 |
| NT‐proBNP, pg/mL | 254.6 (56.4–1061) | 197.4 (37.1–648.8) | 1061 (224.0–1383.0) | 0.0661 |
| Radiological findings | ||||
| GGO with reticular and/or interlobular septal thickening in unilateral lung | 4 (8.9) | 3 (8.8) | 1 (9.1) | 1.0000 |
| GGO with reticular and/or interlobular septal thickening in bilateral lungs | 40 (88.9) | 30 (88.2) | 10 (90.9) | 1.0000 |
| Pleural effusion | 4 (8.9) | 2 (5.9) | 2 (18.2) | 0.2470 |
| Nodule | 10 (22.2) | 9 (26.5) | 1 (9.1) | 0.4087 |
| Thoracic lymphadenopathy | 5 (11.1) | 5 (14.7) | 0 (0.0) | 0.3131 |
| Pleural thickening | 2 (4.4) | 2 (5.9) | 0 (0.0) | 1.0000 |
| Pericardial thickening | 3 (6.7) | 3 (8.8) | 0 (0.0) | 0.5651 |
| Electrocardiographic findings | 14 (31.1) | 8 (23.5) | 6 (54.6) | 0.0707 |
| Arrhythmia | 6 (13.3) | 3 (8.8) | 3 (27.3) | 0.1459 |
| ST segment abnormalities | 6 (13.3) | 3 (8.8) | 3 (27.3) | 0.1459 |
| Right bundle branch block | 3 (6.7) | 2 (5.9) | 1 (9.1) | 1.0000 |
| QT prolongation | 2 (4.4) | 1 (2.9) | 1 (9.1) | 0.4333 |
Data are presented as the median (interquartile), or number (%), where appropriate.
ALT, alanine aminotransferase; AST, Aspartate aminotransferase; LD, lactate dehydrogenase; PT, prothrombin time; APTT, activated partial thromboplastin time; hs‐TNI, high‐sensitivity troponin I; CK‐MB, creatinine kinase–myocardial band; NT‐proBNP, N‐terminal pro–brain natriuretic peptide; GGO, ground‐glass opacity.